Is UroGen Pharma Ltd. overvalued or undervalued?

As of 9 November 2020, UroGen Pharma Ltd. has moved from a grade of "does not qualify" to "risky." The company is currently considered undervalued, despite its negative financial ratios. Key ratios include a Price to Book Value of -7.31, an EV to EBIT of -2.47, and an EV to EBITDA of -2.50, indicating significant challenges in profitability and capital efficiency.
In comparison to its peers, UroGen Pharma's P/E ratio stands at -4.41, while Avidity Biosciences, Inc. has a P/E of -9.59 and AnaptysBio, Inc. at -4.98, highlighting a similar risk profile among these companies. Although UroGen's recent stock performance has been volatile, it has shown a remarkable 241.29% return over the past month, which contrasts sharply with the S&P 500's 3.83% return during the same period, suggesting potential for recovery despite the current valuation challenges.